
Eben Rosenthal
Professor and Chair, Dept. of Otolaryngology Head and Neck Surgery · Vanderbilt University Medical Center
Credentials: · · · · ·
History
- Present
Dept. of Otolaryngology Head and Neck Surgery Department · Vanderbilt University Medical Center
- Present
Department of Otolaryngology–Head and Neck Surgery · Vanderbilt University Medical Center
- Present
Department of Otolaryngology–Head and Neck Surgery · Vanderbilt University Medical Center
- 2000–2001
- 1995–2000
Otolaryngology
- 1994–1995
Research
Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Clinical Cancer Research · 2015 · First of 16 authors · Corresponding · 390 citations
Beyond the margins: real-time detection of cancer using targeted fluorophores
Review · Nature Reviews Clinical Oncology · 2017 · 350 citations
Real-time fluorescence imaging in intraoperative decision making for cancer surgery
Review · The Lancet Oncology · 2021 · 206 citations

79 papers

48 papers

33 papers · 2 as a fellow

32 papers · 25 as a resident
- MW
29 papers
- BM
23 papers · 8 as a fellow

22 papers

22 papers
Grants
- 2024–2029
Secondary Molecular Imaging (SMI) for Head and Neck Cancer
National Cancer Institute · R01
Contact PI · $1.1M · Vanderbilt University Medical Center
- 2022–2027
Targeted Dual Modality Imaging for Detection and Removal of Head and Neck Cancer
National Cancer Institute · R01
Contact PI · $2.1M · Vanderbilt University Medical Center
- 2019–2024
Optical Imaging to Improve Surgery & Targeted Therapy in Brain Tumors
National Cancer Institute · R01
Contact PI · $2.9M · Stanford University
- 2023–2024
American Head and Neck International Conference
National Institute of Dental and Craniofacial Research · R13
Contact PI · $8K · Vanderbilt University Medical Center
Clinical trials
- 2026–2027
Principal investigator · Not yet recruiting
Stanford University
- 2026–2031
Principal investigator · Recruiting · Phase 1
Vanderbilt-Ingram Cancer Center
- 2026–2030
Principal investigator · Recruiting · Phase 1
Vanderbilt-Ingram Cancer Center
- 2025–2029
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Principal investigator · Recruiting · Phase 1
Vanderbilt-Ingram Cancer Center


